4Clipstone NA, Crabtree GR. Identification of calcineurin as a key signal enzyme in T-lymphocyte activation. Nature, 1992,357:695
5Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995,29(6) :404
6Shiraga T, Matsuda H, Nagase K, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat. dog and human liver microsomes.Biochem Pharmacol, 1994,47 (4): 727
7Min DI, Chen HY, Lee MK, et al. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacotherapy, 1997, 17(3) :457
8Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation, 1995, 60(12): 1384
9Pirsch JD, Miller J, Deierhoi MH. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation, 1997, 63(7):977
7Grenier FC,Luczkiw J,Bergmann M,et al.A whole blood FK506 assay for the IMx analyzer[].Transplantation Proceedings.1991
8Takahara S,Takano Y,Montabarrik A,et al.Blood level monitoring of FK506 on kidney transplant recipients[].Nippon Hinyokika Gakkai Zasshi.1993
9Laskow DA,Vincenti F,Neylan JF,et al.An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group[].Transplantation.1996
